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Abstract
Background:  IgA nephropathy (IgAN) or Berger's disease, is the most common
glomerulonephritis in the world diagnosed in renal biopsied patients. The involvement of genetic
factors in the pathogenesis of the IgAN is evidenced by ethnic and geographic variations in
prevalence, familial clustering in isolated populations, familial aggregation and by the identification
of a genetic linkage to locus IGAN1 mapped on 6q22–23. This study seems to imply a single major
locus, but the hypothesis of multiple interacting loci or genetic heterogeneity cannot be ruled out.
The organization of a multi-centre Biobank for the collection of biological samples and clinical data
from IgAN patients and relatives is an important starting point for the identification of the disease
susceptibility genes.
Description: The IgAN Consortium organized a Biobank, recruiting IgAN patients and relatives
following a common protocol. A website was constructed to allow scientific information to be
shared between partners and to divulge obtained data (URL: http://www.igan.net). The electronic
database, the core of the website includes data concerning the subjects enrolled. A search page
gives open access to the database and allows groups of patients to be selected according to their
clinical characteristics. DNA samples of IgAN patients and relatives belonging to 72 multiplex
extended pedigrees were collected. Moreover, 159 trios (sons/daughters affected and healthy
parents), 1068 patients with biopsy-proven IgAN and 1040 healthy subjects were included in the
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IgAN Consortium Biobank. Some valuable and statistically productive genetic studies have been
launched within the 5th Framework Programme 1998–2002 of the European project No. QLG1-
2000-00464 and preliminary data have been published in "Technology Marketplace" website: http:/
/www.cordis.lu/marketplace.
Conclusion: The first world IgAN Biobank with a readily accessible database has been constituted.
The knowledge gained from the study of Mendelian diseases has shown that the genetic dissection
of a complex trait is more powerful when combined linkage-based, association-based, and
sequence-based approaches are performed. This Biobank continuously expanded contains a sample
size of adequately matched IgAN patients and healthy subjects, extended multiplex pedigrees,
parent-child trios, thus permitting the combined genetic approaches with collaborative studies.
Background
IgA nephropathy (IgAN) or Berger's disease is the most
common glomerulonephritis worldwide in patients
undergoing renal biopsy. Diagnosis is based on the occur-
rence of mesangial deposits of IgA in the glomeruli in the
presence of recurrent episodes of intra-infectious macro-
scopic hematuria or persistent microscopic hematuria
and/or proteinuria. The frequency of this disease is renal
biopsy policy-dependent [1]. In some countries, the
majority of patients with recurrent macroscopic hematu-
ria undergo renal biopsy only in the presence of proteinu-
ria or mild renal insufficiency. In Eastern countries,
however, many young subjects with persistent micro-
scopic hematuria and mild proteinuria often receive renal
biopsy. This is not the policy in most Western countries,
in addition often asymptomatic subjects with persistent
urinary abnormalities (microhematuria and/or proteinu-
ria) decline renal biopsy. This large variability in symp-
toms induces different approaches in performing renal
biopsy. Nevertheless, renal biopsy practice is not the sole
cause of the different disease worldwide prevalence. Strik-
ing ethnic variation in prevalence [2-6] along with famil-
ial clustering [7-9] are suggestive of an important role of
the genetic component in the pathogenesis of the disease.
IgAN may occur in a sporadic or a familial form according
to the clinical evidence that one or more subjects belong-
ing to the same family are affected by biopsy-proven IgAN
[10-12]. Moreover, sub-clinical renal abnormalities are
often evidenced among relatives of IgAN patients
[9,11,13].
Genetic analysis of large pedigrees of IgAN families is con-
sidered the most promising approach to identify IgAN
susceptibility genes. The genome wide scanning in 30
large extended IgAN multiplex families (24 from Italy and
6 from United States) was performed by Gharavi et al
[14]. This study identified the locus, called IGAN1,
located on chromosome 6q22–23 in linkage with IgAN. It
yielded a significant peak Lod-score of 5.6, with 60% of
families linked, assuming an autosomal dominant mode
of inheritance with reduced penetrance. This mode of
inheritance of familial IgAN is more consistent with the
involvement of a single gene with a large effect located in
IGAN1. Nevertheless, multifactorial determination, with
the interplay of many genes, each conferring a small effect
cannot be excluded. The knowledge gained from the study
of Mendelian diseases has shown that genetic dissection
of a complex trait is more powerful when combined link-
age-based, association-based, and sequence-based
approaches are performed [15]. Association-based studies
are possible when a large sample size of adequately
matched IgAN patients and healthy subjects is collected.
Prior insight into the pathogenesis of the disease allows to
establish the candidate genes to be studied according to
their known or suspected function. Over the past decade,
a shift has occurred away from case-control association
studies, towards family-based designs in which extended
pedigrees, relative-pairs and parents-child trios are used to
test for association. For this purpose, different powerful
and sensitive methods of analysis have been developed,
most of which are based on the trasmission/disequilib-
rium test (TDT) [16].
Considering the possibility of identifying IgAN suscepti-
bility genes a group of European scientists, specialists in
this disease, constituted an IgAN Consortium and organ-
ized a Biobank project recruiting biological samples and
clinical data from IgAN patients and relatives. This report
describes the creation of the first Biobank with a readily
accessible database of the most common worldwide
glomerulonephritis, a rare disease which requires a multi-
centre project organization.
Construction and content
The IgAN Consortium was based on the constitution of a
collaborative study group including expert nephrologists
from Italy (FPS, FS, GMF), Germany (JF) and Greece (EA),
geneticists from Italy (AA, LB, GC, GMG) and Germany
(KZ). The European project No. QLG1-2000-00464 was
funded by the 5th Framework Programme 1998–2002.
Additional funds were obtained in Italy from MIUR (Min-
istero dell'Istruzione, Universita' e Ricerca PRIN 2001-
067748; L.488/92 Cluster 03; FIRB 2001-RBNE013JYN).BMC Nephrology 2005, 6:14 http://www.biomedcentral.com/1471-2369/6/14
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The main aim of the project was to constitute a genomic
DNA bank of well characterized IgAN patients and their
relatives from three different European countries (Ger-
many, Greece and Italy) to be used for genetic studies. The
following objectives were reached:
1. a) Definition of a common protocol for the diagnosis
of familial, suspected and sporadic IgAN. IgAN was diag-
nosed on the basis of either recurrent episodes of macro-
scopic hematuria concomitant with upper respiratory
tract and other infections or permanent microscopic
hematuria with/out proteinuria. Mesangial glomerular
IgA deposits in the renal biopsy and absence of systemic
or hepatic diseases confirmed the diagnosis. Relatives of at
least three generations received urinalysis. All relatives
with persistent microscopic hematuria received an Addis
count under contrast phase microscopy (glomerular
hematuria was confirmed at least three times) and renal
ultrasound. Relatives with suspected IgAN were informed
and received renal biopsy to confirm the diagnosis. All
subjects were categorized as: (I) affected subjects with
biopsy-proven disease; (II) subjects probably affected by
IgAN when persistent microscopic hematuria without
biopsy-proven glomerulonephritis, or chronic renal insuf-
ficiency or ESRD treated with hemo or peritoneal dialysis,
or renal transplantation after biopsy-proven IgAN or
unknown glomerulonephritis, or death caused by chronic
uremia, occurred; (III) non-affected subjects in the
absence of urinary abnormalities; (IV) subjects with
unknown status, who refused participation or in the
absence of clinical information and laboratory findings.
Familial IgAN was diagnosed when at least 2 family mem-
bers had biopsy-proven IgAN. Suspected IgAN families
were considered those in which one subject was a biopsy-
proven IgAN patient and others were probably affected,
were awaiting or refused renal biopsy, or had urinary
abnormalities that did not justify its execution. They were
checked systematically once a year. Sporadic IgAN was
diagnosed when the disease occurred only in the patient
and relatives were negative by urinalysis. b) Layout of a
booklet containing information, letter of informed con-
sent and instructions for the collection of blood samples.
c) Definition of a data sheet for the collection of personal
data, clinical and laboratory findings.
IgAN Consortium website structure Figure 1
IgAN Consortium website structure.BMC Nephrology 2005, 6:14 http://www.biomedcentral.com/1471-2369/6/14
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2. Constitution of the Biobank. Blood samples from all
the participants after informed consent (disclosing infor-
mation about the research objectives, benefits and risks)
were obtained. Thirty ml of peripheral blood was drawn
from each subject aged more than 15 years and 15 ml
from each younger subject. Plasma and serum samples
were stored at -80°C in order to be used for the biochem-
ical (inflammatory cytokines and chemokines) and
immunological parameter measurements (complement
components, IgA serum level, IgA galactosylation) as
required. EDTA tubes were used to collect blood samples
for DNA isolation. The EDTA anticoagulated blood sam-
ple from each subject was divided into three aliquots, two
of which were processed for DNA extraction, in a separate
manner, using commercial kits. The first DNA sample was
stored in ethanol 75% at 4°C, in the form of a pellet. The
second one was suspended in deionised nuclease free
water and subdivided into two aliquots ready to use. They
were independently stored at 4°C and at -20°C. Storage at
4°C prevents degradation due to the mechanical stress of
freezing and thawing and storage at -20°C inhibits possi-
ble DNase activity. This method was adopted to guarantee
an adequate quality DNA sample and long term storage.
Moreover, the last aliquot of whole blood was stored at -
20°C in order to isolate a DNA sample whenever needed.
DNA was isolated in the Bari, Trieste, Genova and Aachen
laboratories. F.P.S., F.S., A.A., J.F., E.A. oversaw the accu-
racy of the DNA sample collection. All the IgAN patients
and relatives, from whom DNA samples were collected,
were listed in the database and were available to the IgAN
Consortium partners and to the investigators proposing
collaborative studies. The protocol was approved by the
local Ethical Committees. The documents regarding each
local Ethical Committee who have given approval for the
study, in their original language, have been disclosed as a
window in the IgAN Consortium website [17], purposely
constructed for this study.
3. Construction of a website to share scientific informa-
tion between partners and to divulge obtained data to the
community. The IgAN Consortium website was designed
and realized by Apulia Biotech (Valenzano, Bari, Italy)
and is managed by Altanet SRL (Altamura, Bari, Italy)
internet provider. The website includes three sections: (a)
Information, (b) Registry and (c) News (fig. 1) all readily
accessible for public vision. Section (a) contains guide-
lines for the collection of blood samples, information
about the disease and the informed consent form to be
compiled. Section (b) encloses the electronic database for
the collection of all personal and clinical data of each
enrolled subject. The IgAN Consortium partners are given
personal passwords to insert and modify information
included in the database. This section is also provided
with a search page (clinical finding search page) that gives
free access to the database. Groups of IgAN patients can be
selected according to their specific characteristics. The
clinical history can be viewed observing the confidential-
ity of each subject. Important information about IgAN
Consortium policy for collaborative studies are given.
This section is periodically updated in all its parts. Section
(c) is devoted to public dissemination of achieved data. It
presently includes the report of three years of activities.
4. Construction of an electronic database, for the collec-
tion of personal data, clinical, histological and laboratory
findings. The database was developed in Filemaker Pro
5.0 obtaining a powerful cross platform relational data-
base. The website interface was realized by using Lasso by
Omnipilot Software Inc as the local data markup language
(LDML) that connected our HyperText Markup Language
(HTML) pages to the Filemaker database. 4D Webstar was
used as Internet server. It encloses the list of IgAN patients
and relatives enrolled, and the familial IgAN pedigrees.
Pedigrees were drawn using the software Cyrillic 2.1. Each
collected family and subject was univocally identified by
a sequence of three numeric codes: partner unit, family
and subject code. Each partner identified a staff member,
responsible for the attribution of the codes. Progressive
numeric codes for families and subjects were assigned
according to the time of enrolment in this study. All the
data collected for each enrolled subject at the onset of the
disease, at the time of the renal biopsy and at the available
follow up are included in the database. Serum creatinine
(sCR) and daily proteinuria were obtained from IgAN
patients at different times. Daily proteinuria was defined
as mild (<1 g), moderate (1–3 g) and severe (>3 g). Renal
function was evaluated by creatinine clearance obtained
using the Cockcroft formula [18]. According to the K-
DOQI guidelines [19] the stages of chronic kidney disease
were classified as kidney damage with normal renal func-
tion (creatinine clearance ≥ 90 ml/min), mild (60–89 ml/
min), moderate (30–59 ml/min) and severe impaired
renal function (15–29 ml/min) and kidney failure (<15
ml/min or dialysis). According to the 2003 ESH/ESC
hypertension guidelines [20], subjects were defined
hypertensives when blood pressure was above 130/85
mmHg or when they received anti-hypertensive drugs.
Three outcome measures were considered in the follow up
of the IgAN patients: chronic renal insufficiency, dialysis
and renal transplant. Renal biopsy specimens were scored
considering the severity of glomerular, tubulointerstitial
and vascular lesions. According to the WHO classification
3 histological grades (G) were identified: a) G1 (mild dis-
ease); b) G2 (moderate disease); c) G3 (severe disease)
[21,22]. In the search page of the website Registry-section
the biopsy-proven IgAN patients (BP-IgAN) may be
selected according to these clinical and laboratory charac-
teristics at the time of the renal biopsy or according to the
main outcome measures. The result page included three
important links: the "pedigree" field allows the visualiza-BMC Nephrology 2005, 6:14 http://www.biomedcentral.com/1471-2369/6/14
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tion of the familial IgAN cases; the "info" field introduces
the complete clinical history of each patient and the "fol-
low up" field links directly to the data at different follow up
times for each patient.
A medical geneticist collaborating with each nephrology
unit involved in the project offered genetic counselling to
IgAN patients and relatives. The main purpose of the
counselling is to give information on a complex genetic
disease such as IgAN and to illustrate the Biobank objec-
tives, underlining that the genetic tests will not give an
immediate answer to the possibility of developing the dis-
ease or not. The clinicians explained to all patients the
potential familial incidence of the disease and invited
their relatives to the genetic counselling session in which
a clinical screening was proposed for all relatives. In addi-
tion, they were informed on the possibility to be enrolled
in this Biobank. For this purpose, the aims of the project
were discussed in lay terms with respect to the risk for the
involved subjects. It was clearly stated that the subjects
tested would not benefit personally from the genetic stud-
ies. Financial rewards were not offered to encourage par-
ticipation. Patients and relatives were informed that the
DNA would be used only for the present project i.e.
genetic dissection of IgAN. Moreover, a detailed descrip-
tion of the genetic studies to be carried out was given.
Informed consent was signed after the genetic counsel-
ling.
Normal subjects were recruited among healthy blood
donors with negative urinalysis and no history of renal
disease, diabetes, hypertension or metabolic disorders.
They were matched for age, gender and ethnicity to the
IgAN patient population enrolled. They were scrupulously
informed about the aim of the study. They gave a written
informed consent for DNA collection and for the han-
dling of their genetic and personal data for the present
project. The collection of DNA samples is still underway.
The IgAN Consortium collected DNA samples from IgAN
patients and relatives belonging to at least three genera-
tions, with particular attention paid to the collection of all
first degree relatives. DNA samples, collected from the
Table 1: Collection of DNA samples from IgAN patients, relatives and apparently healthy controls obtained by the IgAN Consortium.
Partner No. Local site IgAN families No. Trios No. Biopsy-proven 
IgAN patients No.
Controls No.
1 Bari, Italy 32 (43*) 91 456 215
2 Brescia, Italy 31(5*) 47 360 204
3 Trieste, Italy 4(3*) 6 116 221
4 Aachen, Germany 2(8*) 9 62 200
5 Thessaloniki, Greece 3(4*) 6 74 200
Total samples 72(63*) 159 1068 1040
*Number in brackets represents additional suspected IgAN families. These are families in which one member is affected by biopsy-proven IgAN and 
others -not biopsied have recurrent macroscopic hematuria episodes in concomitance of upper respiratory tract infections or persistent 
microscopic hematuria.
Table 2: Distribution of pairs of relatives in 72 IgAN families according to genetic relationship and IgAN.
IgA Nephropathy status
Relationship A/A A/P A/N N/N Total pair
Spousal 0 2 25 35 62
Parent-offspring 20 19 147 211 397
Sibling 44 32 168 185 429
Half-sibling 00404
Granparental 045 8 9 9 8
Avuncular 8 22 170 382 582
Cousin 56 4 0 2 3 8 2 8 9
Other 17 9 141 545 712
Total Pairs 94 94 700 1685 2573
(A) affected subjects with biopsy-proven disease; (P) subjects probably affected by IgAN when persistent microscopic hematuria without biopsy-
proven glomerulonephritis, or chronic renal insufficiency or ESRD treated with hemo or peritoneal dialysis, or renal transplantation after biopsy-
proven IgAN or unknown glomerulonephritis, or death for chronic uremia, occurred; (N) non-affected subjects in the absence of urinary 
abnormalities.BMC Nephrology 2005, 6:14 http://www.biomedcentral.com/1471-2369/6/14
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research units are listed in table 1. All the subjects enrolled
were of Caucasian origin and belonging to different Euro-
pean geographic area: North and South Italy (Lombardia,
Piemonte, Friuli Venezia Giulia and Puglia region),
Greece (Thessaloniki), Germany (Nordrhein, Westfalia
region). DNA samples from 72 multiplex IgAN families,
63 suspected IgAN families, 1068 patients with biopsy-
proven IgAN were obtained. The number of collected rel-
atives for each family enrolled was different. Fifty-one
IgAN families have less than 10 relatives, 17 include a
number of relatives ranging from 10 to 20 subjects and
finally 4 IgAN families have more than 20 relatives. Forty-
nine suspected IgAN families have less than 10, 13 less
than 20 and 1 family has more than 20 relatives. A large
sample size was obtained in the form of trios (son/daugh-
ter affected and healthy parents). A large number of
healthy blood donors adequately matched for age, gender
and origin to the patient populations were recruited as
controls in each area.
Seventy-two IgAN families included DNA samples from
94 pairs of biopsy proven IgAN patients and a total
number of 2573 pairs of relatives. Table 2 shows the dis-
tribution of pairs of relatives collected from the 72 IgAN
families according to genetic relationship and disease.
A gradually increasing number of DNA samples collected
during the first three years of our project (from beginning
of October 2000 to the end of December 2003) is shown
in figure 2. Some valuable and statistically productive
genetic studies have been launched within the 5th Frame-
work Programme 1998–2002 of the European project No.
QLG1-2000-00464. Case-control and family-based asso-
ciation studies investigating the possible role of some
Th1/Th2/Th3/TR-type, and of monocyte/macrophage
cytokines gene polymorphisms and Core1 β 1,3- Galacto-
syltransferase (β1.3 C1GALT1) gene are presently under
way. Some preliminary data are publicly available in the
"Technology Marketplace" website [23]. Further investiga-
tions needs to strengthen the data obtained.
Utility and discussion
We have described the constitution of the European IgAN
Biobank which is the first DNA bank created in the world
by the multi-centre collaborative project for this disease.
The main aim of this project was to organize a genomic
DNA bank of biopsy-proven IgAN patients and their fam-
ily members belonging to three different geographic areas
of Europe (Germany, Greece and Italy). The Biobank has
taken care of ethical aspects since the collection and stor-
age of personal and genetic information follow the indi-
cations of the Council of Europe, as stated in the
Convention on human rights and biomedicine (Nov 19,
1996), and those of UNESCO, as reported in the Declara-
tion on human genome (Nov 11, 1997). In addition, the
handling of personal and genetic data collected follow the
indications and norms existing in each participating coun-
try.
The IgAN Consortium has set up a website to allow the
partners to share the scientific information and for public
dissemination of all the information related to the disease
and new achieved data [17]. The accessible database with-
out restriction permits to share clinical data of IgAN
patients with other participating centres. A search page
supports the investigators in selecting IgAN patient groups
with respect to specific clinical data to perform prospec-
tive and retrospective studies.
Studies that seek to identify disease genes can be divided
into two categories: linkage and association studies. Link-
age studies speculate on the co-segregation of marker alle-
les and disease of interest in multiplex families while
association studies detect linkage disequilibrium between
marker and disease loci using case-control and/or family-
based designs. In the simplest design, genetic variant fre-
quencies of exposure are compared to diseased cases and
non diseased controls. This approach, highly effective in
detecting genes of modest effect, is susceptible to "popu-
lation stratification bias" arising from differences in the
genetic background of cases and controls. The distribution
of alleles in a population is related to the ethnic and social
background and geographical origin of their parents.
There is a great debate on the possibility of analysing iso-
lated populations for genetic studies, which may be
homogeneous such as Finnish, Icelanders, Sardinians, or
heterogeneous populations such as in the case of the UK
Biobank [24-28]. Researchers reason that in a population
such as Iceland's (270,000 individuals), which expanded
DNA samples collected from the beginning of the IgAN Con- sortium European project Figure 2
DNA samples collected from the beginning of the IgAN Con-
sortium European project.BMC Nephrology 2005, 6:14 http://www.biomedcentral.com/1471-2369/6/14
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from a relatively small number of founders and that did
not experience significant immigration, there should be
fewer opportunities for particular markers and disease
genes to have become separated down the generations.
On the other hand some investigators recently provide
results that isolated populations are unlikely to be very
different from more mixed populations in terms of link-
age disequilibrium [29]. Tom Meade of the Medical
Research Council (MRC) in Britain, acknowledged that
heterogeneous populations will have some advantage
because the results will be representative of the popula-
tion as a whole [25]. The family-based approach in which
controls are represented by healthy family members has
attracted considerable attention since it minimizes popu-
lation stratification bias and it avoids making erroneous
conclusion. In our Biobank we proposed to collect DNA
samples from patients, their relatives and an adequate
number of controls of different geographic areas to enable
each research unit, independently, to perform case-con-
trol and/or family-based association studies in a popula-
tion belonging to a restricted area. Whenever statistical
evidence for a genetic association was obtained, the same
data would be checked for the populations collected in
other geographic areas. This organization could be highly
representative of the IgAN genetic background and more
powerful in the detection of weak genetic effects.
It is the policy of the IgAN Consortium to favour further
collaborative genetic studies. Other investigators not
belonging to the IgAN Consortium, who would like to
have access to the DNA Bank for genetic studies, must sub-
mit the study design to the scientific committee repre-
sented by the principal investigators of the IgAN
Consortium research units (F.P.S., F.S., A.A., J.F., E.A.,
K.Z., L.Z.) [see Additional file 1] and must agree to the
terms for data publication. Adequate procedures are used
to minimize inadvertent release of personal information
and to guarantee confidentiality of genetic results, such as
disease genetic predisposition or family relationships
(non-paternity, adoption). All results published must not
reveal the patient's identity.
The availability of genetic material from participants in
large epidemiological studies represents an invaluable
resource for exploring genetic and environment influence
on disease risk. In fact, the world's largest study on cancer
is the multi-centre European Prospective Investigation
into Cancer and Nutrition (EPIC), which started recruit-
ing in the early 1990's and has now available more than
500,000 individuals [30]. This has allowed the project to
move onto the study of genetics since its sample includes
350 cases of colon cancer and nearly 2000 of breast can-
cer. Our data collection of more than 1000 individuals
with IgAN is close to the above mentioned EPIC data for
each disease. Robert Hoover, director of epidemiology
and biostatistics at the National Cancer Institution at
Bethesda, Maryland, defines a large epidemiological study
as a study which generates 1000 to 1500 individuals with
a particular cancer in a reasonable time [26]. Keeping this
in mind we collected DNA samples from more than 1000
IgAN patients. However, our Biobank will continue to
enrol additional patients in the future for potential strati-
fication of our population with respect to specific pheno-
types thus promoting correlations with discovered
genotypes.
During these last ten years many biobanks have been
organized but there is no system for comprehensive regis-
tration of the DNA banks. Surely many case-control and
family-based association studies will originate from these
DNA banks in the future. The IgAN Consortium Biobank
has allowed us to carry out a linkage study and various
case-control and family-based association studies whose
investigation is currently under way. We think that the
inclusion of all DNA banks in a public registry might cre-
ate many advantages for scientists and patients as follows:
I) people involved in the scientific and clinical activity of
a certain diseases may have a point of reference; II) net-
work of scientists involved in basic and clinical research
may obtain many advantages by the public registry; III)
patients may contribute by donating their DNA sample to
the bank thus increasing the number of collected DNA
samples for future studies; IV) the public registry would be
available to contribute knowledge which can be general-
ised regardless results from genetic studies. (Table 3)
Conclusion
IgAN is a complex disorder with both genes and environ-
ment contributing in the pathogenesis. A Biobank, depos-
itory of a large number of DNA samples from IgAN
patients and their relatives, together with a database
including their personal and clinical data, has a crucial
role in the genetic dissection of IgAN. Such an organiza-
tion favours and stimulates collaborative studies. The con-
stitution of a well organized and multi-centre biobank, an
adequate choice with respect to design strategies and
improved genotyping methods could greatly enhance the
current understanding of the molecular genetic basis of
this disease. Finding complex disease genes may allow us
to determine which subjects are at risk of IgAN before that
genetic susceptibility is converted into disease. In addi-
tion, the identification of such genes should reveal more
about the molecular pathway causing the disease, thus
suggesting new and relevant targets for more efficient drug
treatment.
Availability and requirements
A password is not required to search the IgAN Consortium
website database, the password is only necessary to insert
and to modify data [17].BMC Nephrology 2005, 6:14 http://www.biomedcentral.com/1471-2369/6/14
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